ReviewCurrent neuropharmacology2016

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Jean-Marc Taymans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.